Redox nanodrugs alleviate chronic kidney disease by reducing inflammation and regulating ROS

Biomater. Sci., 2024, Advance Article
DOI: 10.1039/D4BM00881B, Paper

Open Access

&nbsp This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

Qin Wang, Xuedan Nie, Yifan Song, Haiyan Qiu, Liting Chen, He Zhu, Xueli Zhang, Mengru Yang, Xiaohui Xu, Peidan Chen, Chao Zhang, Jia Xu, Yeping Ren, Wenting Shang
A novel ultrasmall redox-active nanodrug (Tac@C-Mn₃O₄) protected mitochondria, scavenged excess ROS, maintained cellular redox homeostasis, and inhibited the oversecretion of pro-inflammatory cytokines, thereby restoring renal function.
To cite this article before page numbers are assigned, use the DOI form of citation above.
The content of this RSS Feed (c) The Royal Society of Chemistry